|Bid||15.01 x 1400|
|Ask||15.97 x 1200|
|Day's Range||14.82 - 19.46|
|52 Week Range||8.34 - 53.75|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 16, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||38.55|
New York, New York--(Newsfile Corp. - March 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Immunovant, Inc. (NASDAQ: IMVT) f/k/a Health Sciences Acquisitions Corporation (NASDAQ: HSAC) between October 2, 2019 and February 1, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District ...
Shares of clinical-stage biopharmaceutical company Immunovant (NASDAQ: IMVT) are on fire on Monday. Immunovant did not report any news, but its majority stakeholder, Roivant Sciences, announced that it would offer to buy out the remaining shares of Immunovant it does not already own. Roivant Sciences is a privately owned biopharmaceutical company that currently owns 57.5% of the outstanding shares of Immunovant.
LOS ANGELES, CA / ACCESSWIRE / March 8, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. ("Immunovant" or "the Company") (NASDAQ:IMVT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.